Moderna Vaccine Import in India | Moderna Vaccine: Country to get one more vaccine, Cipla gets DCGI nod for import of ‘Moderna Vaccine’, Cipla/Moderna gets DCGI nod for import of COVID19 vaccine
Moderna vaccine may also be imported in the country soon
- Moderna’s vaccine relies on messenger RNA
- Cipla had on Monday sought permission from DCGI to import the vaccine.
- This vaccine can be given to people over the age of 18
New Delhi: Moderna’s vaccine may also be imported into the country soon. The Drug Controller General of India (DCGI) has given approval to Cipla to import Moderna’s vaccine, which can be administered to people above the age of 18 years. The company had formally knocked on the door for its permission in India.
American vaccine company ‘Moderna’ had sought regulatory approval for its anti-Covid-19 vaccine in India and Cipla had applied for authorization to import, market the vaccine.
Moderna’s vaccine relies on messenger RNA, which programs cells to develop immunity against the coronavirus.
Cipla had on Monday sought permission from DCGI to import the vaccine. Last week, the Delhi government also appealed to the central government to allow international vaccine candidates like Pfizer, Moderna and Johnson & Johnson. The results of clinical trials conducted regarding this vaccine show that this vaccine is more than 90 percent effective against cases with symptoms of corona infection.
Moderna has reported in a separate letter that the US has agreed to donate a specific number of doses of its Kovid-19 vaccine to the Indian government through ‘Covax’ for use here. It is noteworthy that Kovax is a global initiative for equitable distribution of the Kovid-19 vaccine.
‘Moderna’s protein-based COVID vaccine is safe for children to use’
This claim has been made in a research on baby rhesus macaques. The study by a team of scientists from the University of North Carolina at Chapel Hill, Weill Cornell Medicine and New York-Presbyterian reported that both vaccines elicited strong neutralizing antibody responses to SARS-CoV-2 with baby rhesus macaques , the virus that causes COVID-19. It found that antibody responses persisted for up to 22 weeks. Research published in the journal Science Immunology suggests that vaccines for young children are an important and safe tool to reduce epidemics.
#Moderna #Vaccine #Import #India #Moderna #Vaccine #Country #vaccine #Cipla #DCGI #nod #import #Moderna #Vaccine #CiplaModerna #DCGI #nod #import #COVID19 #vaccine